Items where authors include "de Bruin-Weller, M."

Article

Simpson, E.L., Silverberg, J.I., Thyssen, J.P. et al. (10 more authors) (2023) Efficacy and safety of abrocitinib in patients with severe and/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE trial. American Journal of Clinical Dermatology, 24. pp. 609-621. ISSN 1175-0561

Silverberg, J.I., Simpson, E.L., Guttman-Yassky, E. et al. (15 more authors) (2021) Dupilumab significantly modulates pain and discomfort in patients with atopic dermatitis : a post hoc analysis of 5 randomized clinical trials. Dermatitis, 32 (1S). S81-S91. ISSN 1710-3568

de Bruin-Weller, M., Simpson, E.L., Cork, M. orcid.org/0000-0003-4428-2428 et al. (6 more authors) (2020) Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. Journal of the American Academy of Dermatology, 83 (5). pp. 1499-1501. ISSN 0190-9622

Akinlade, B., Guttman-Yassky, E., de Bruin-Weller, M. et al. (25 more authors) (2019) Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology, 181 (3). pp. 459-473. ISSN 0007-0963

Cork, M.J. orcid.org/0000-0003-4428-2428, Eckert, L., Simpson, E.L. et al. (14 more authors) (2019) Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Journal of Dermatological Treatment. ISSN 0954-6634

de Bruin-Weller, M., Thaçi, D., Smith, C.H. et al. (12 more authors) (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). British Journal of Dermatology , 178 (5). pp. 1083-1101. ISSN 0007-0963